Australian NSP Survey National Data Report 2021 – 2025

The Australian Needle Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) (antibody and RNA) and sexual and injecting risk behaviour among people who inject drugs (PWID) attending needle syringe programs (NSPs) in Australia.

Conducted annually over a one to two week period, all clients attending participating NSPs are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody and HCV RNA testing.

This report presents national and state/territory data for the period 2021 to 2025.

Key findings

In 2025, 53 Australian Needle Syringe Programs (NSPs) participated in the ANSPS and 1,781 NSP attendees completed the survey. The response rate was 35%.
HIV antibody prevalence remained low and stable nationally, ranging from 1.5% to 2.1% over the period 2021 to 2025.
HCV antibody prevalence declined from 45% in 2023 to 32% in 2025, following change to the testing assay in 2023.
The proportion of respondents with detectable HCV RNA declined from 16% in 2021 to 7% in 2025.
Among respondents assessed as eligible for HCV treatment, the proportion who reported a lifetime history of HCV treatment increased, from 62% in 2021 to 81% in 2025.

Australian NSP Survey National Data Report 2021 – 2025 2.24 MB pdf

Report contact